Abstract | OBJECTIVE:
Methamphetamine (MA) use has recently been associated with high levels of psychiatric hospitalization and serious social dysfunction. MA use causes frequent psychotic symptoms, which can be treated with antipsychotics. However, people with intellectual disabilities (ID) are vulnerable to adverse effects resulting from treatment with antipsychotic medications. METHOD: RESULTS: CONCLUSION:
Blonanserin may be an effective and well-tolerated pharmacotherapeutical treatment for patients with MAP comorbid with ID. However, further work is necessary to validate this claim.
|
Authors | Kosuke Okazaki, Manabu Makinodan, Kazuhiko Yamamuro, Tomoyo Takata, Toshifumi Kishimoto |
Journal | Neuropsychiatric disease and treatment
(Neuropsychiatr Dis Treat)
Vol. 12
Pg. 3195-3198
( 2016)
ISSN: 1176-6328 [Print] New Zealand |
PMID | 28008256
(Publication Type: Journal Article)
|